Kiniksa Pharmaceuticals International, plc KNSA Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's other accrued liabilities?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported other accrued liabilities of $20.69M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's other accrued liabilities changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's other accrued liabilities increased by 21.1% year-over-year, from $17.09M to $20.69M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's other accrued liabilities?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's other accrued liabilities has grown at a 259.2% compound annual growth rate (CAGR), from $37K to $22.13M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.